Ziylo is a supramolecular chemistry company that has developed a third ‘biomimetic’ class of glucose binding molecule (GBM). These molecules are at the core of medical devices such as Continuous Glucose Monitors (CGM) and therapeutics such as Glucose Responsive Insulins (GRI). Our platform technology is based on over 20 years of cutting-edge research pioneered by Professor Anthony Davis’ group at the University of Bristol. Inspired by nature’s carbohydrate-binding molecules (lectins), Professor Davis has become a leader in the field of ‘Synthetic Lectins’ – biomimetic molecules that are capable of binding carbohydrates like glucose in water. This award-winning chemistry has been published in Science and Nature Chemistry and has laid the foundation for the discovery our Biomimetic GBM platform.